WO2002064185A2 - VERFAHREN ZUR VERRINGERUNG VON FOLGEKOMPLIKATIONEN BEI DER IMPLANTATION VON GEFÄssSTÜTZEN - Google Patents
VERFAHREN ZUR VERRINGERUNG VON FOLGEKOMPLIKATIONEN BEI DER IMPLANTATION VON GEFÄssSTÜTZEN Download PDFInfo
- Publication number
- WO2002064185A2 WO2002064185A2 PCT/EP2002/001388 EP0201388W WO02064185A2 WO 2002064185 A2 WO2002064185 A2 WO 2002064185A2 EP 0201388 W EP0201388 W EP 0201388W WO 02064185 A2 WO02064185 A2 WO 02064185A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- estradiol
- stent
- stents
- vascular
- vascular support
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
- A61F2002/91541—Adjacent bands are arranged out of phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2220/0008—Fixation appliances for connecting prostheses to the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2230/00—Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2230/0002—Two-dimensional shapes, e.g. cross-sections
- A61F2230/0004—Rounded shapes, e.g. with rounded corners
- A61F2230/0013—Horseshoe-shaped, e.g. crescent-shaped, C-shaped, U-shaped
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00574—Coating or prosthesis-covering structure made of carbon, e.g. of pyrocarbon
- A61F2310/0058—Coating made of diamond or of diamond-like carbon DLC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Definitions
- the invention relates to a method for reducing complications during the implantation of vascular supports, in particular for reducing restenosis and in-
- the invention further relates to a method for producing a stent and a device for coating one or more stents with a coating substance.
- a stent is an implant that supports the vessel (e.g. a blood vessel) from the inside and widens the cross-section of the vessel.
- the vascular supports are currently predominantly connected using appropriately prepared tubes made of metal or material (e.g. surgical stainless steel, tantalum or nitinol) or wound or
- vascular supports can be implanted in different ways.
- the vascular support can be arranged on a carrier and compressed ("crimped") before it is inserted into the vessel.
- the carrier can be a balloon catheter, around which the stent is placed. The compressed stent is then by means of
- the fixation in the vessel is carried out by expanding the stent, for example by means of the balloon catheter, the internal pressure of the balloon catheter being increased, for example, with a hand pump.
- the structure of the stent deforms and the stent remains dimensionally stable after removal of the catheter.
- a similar procedure is preferably used when introducing so-called "self-expandable" stents. in this connection however, the pressurization is eliminated.
- the stent opens either due to existing restoring forces or due to the prevailing environmental conditions (flow, temperature, etc.)
- the stent is expanded and supported on the one hand by the stents used. In this way, a narrowing ("stenosis") of a vessel can be eliminated.
- the stents are coated with various materials such as heparin, collagen or fibrin. This is to further reduce the risk of acute stent thrombosis and restenosis.
- US Pat. No. 6,153,252 describes a method for coating stents. In this method, measures are taken to prevent bridging of the applied layer in openings in the wall of the stent. It is proposed to create a flow through these openings during coating. This is achieved in that a cylindrical body is moved past the inside or outside of the stent while the layer to be applied hardens.
- US Pat. No. 6,153,252 mentions a variety of coating techniques, a variety of different stents, a variety of possible coating substances, and a variety of possible drugs that can be used in connection with a stent.
- the invention has for its object to reduce the complications occurring in the implantation of stents.
- this object is achieved in that 17 ⁇ -estradiol is supplied to the point at which the stent is implanted.
- the invention is based on the knowledge that many of the complications (eg restenosis and in-stent stenosis) in the implantation of vascular supports can be attributed to the pathological growth of the smooth muscles in the tunica media (see FIG. 1) of the vessel , This growth occurs when the inner layer (tunica intima) of the endothelium is injured. It has been shown that an implanted vascular support in the human body is covered with neointima cells and endothelium only after about two months in such a way that a continuous cell surface is formed.
- the invention is further based on the finding that 17ß-estradiol (chemically described as 1,3,5 (10) -estratrien-3,17ß-diol with the chemical formula C 18 H 24 O 2 ) both inhibits the growth of smooth muscles , and also promotes the formation of the protective endothelial layer to such an extent that restenosis and in-stent stenosis can be prevented.
- 17ß-estradiol chemically described as 1,3,5 (10) -estratrien-3,17ß-diol with the chemical formula C 18 H 24 O 2
- both inhibits the growth of smooth muscles and also promotes the formation of the protective endothelial layer to such an extent that restenosis and in-stent stenosis can be prevented.
- the invention thus includes the use of 17ß-estradiol as a vascular healing substance in the implantation of stents. Since 17ß-estradiol is a natural estrogen of the body, the usual problems of biocompatibility are very low.
- 17ß-estradiol can be added either before, during or after the implantation of the stent. However, it is particularly advantageous if the supply coincides with the intervention of the implantation of the vascular support or even simultaneously with the
- the stent is implanted. This means that no further intervention is necessary and it can also be better ensured that 17ß-estradiol actually gets where it is supposed to work.
- the amount of 17ß-estradiol added is preferably chosen so that the action time of the 17ß-estradiol corresponds essentially to the healing time of the vessel.
- an amount of 10-1000 ⁇ g 17ß-estradiol per stent may be suitable. This quantity is depend on whether the 17ß-estradiol should act as a single dose within a few hours or over a longer period of time.
- the delivery of 17 ⁇ -estradiol during implantation of the stent can be accomplished by various known delivery techniques.
- a particularly advantageous method is created by a further aspect of the invention, in which the stent itself is provided with 17 ⁇ -estradiol. This ensures that the supply of 17ß-estradiol can take place simultaneously with the implantation of the stent. It also ensures that the 17ß-estradiol actually gets where it should work.
- the 17ß-estradiol is connected to the stent so that it can take effect after the stent is implanted.
- the 17 ⁇ -estradiol is therefore advantageously provided on the surface of the stent.
- vascular supports have a basic body with a tubular basic shape.
- the base body thus forms an inner surface and an outer surface.
- the 17ß-estradiol can then be provided on the inner surface or on the outer surface of the base body.
- both the inner surface and the outer surface are provided with 17 ⁇ -estradiol.
- the 17ß-estradiol it is advantageous to apply the 17ß-estradiol together with a drug delivery system ("drug elution system") to the stent.
- drug delivery systems integrate the active ingredient (here: 17ß-estradiol) in other substances and the active ingredient can then be released at the implantation site of the stent graft.
- active ingredient here: 17ß-estradiol
- Such drug delivery systems are among others in U.S. Patent 6,153,252 in
- 17 ⁇ -estradiol is
- Coating method applied to the surface of the stent This can then be done either directly on the base body or on a carrier layer.
- a variety of surface coating processes are known which can be used for this purpose. It has been shown that CVD processes (“Chemical Vapor Deposition”) are well suited. In such processes, the substance to be applied is evaporated and is then deposited on the parts to be coated.
- the stents to be coated can be provided together with 17ß-estradiol in a vacuum chamber, whereby evaporation of the 17ß-estradiol is generated, for example by heating the 17ß-estradiol.
- the chamber wall of the vacuum chamber can be heated, causing the precipitation of the
- 17ß-estradiols on the chamber wall can be reduced or avoided.
- the effectiveness of the coating can be increased further by cooling the vascular supports to be coated. If several stents are coated in the vacuum chamber at the same time, they can be cooled by common coolants. These coolants can contain, for example, a cooling water circuit. If the amount of 17 ⁇ -estradiol present on the stents to be coated is to be determined, this can be done by specifying layer thickness parameters by means of which the layer thickness of the 17ß-estradiol produced on the base body is determined. This can of course be done by measuring the respective layer thickness using a known layer thickness measuring method. However, the duration of the coating is advantageously used as the layer thickness parameter.
- the dependence of the layer thickness on the duration of the coating is determined experimentally, although other parameters must of course also be taken into account that can influence this dependence (eg temperature of the 17ß-estradiol, the vascular supports and the wall of the vacuum chamber). These further parameters are then kept constant, so that the layer thickness only depends on the duration of the coating. This process allows the layer thicknesses to be determined and controlled very precisely.
- the coating can therefore take place in a device which has a vacuum chamber
- a device for coating by means of coating substances other than 17 ⁇ -estradiols.
- the 17 ⁇ -estradiol and optionally other substances can be applied to the stent by other known methods, e.g. by spraying or by immersion in solutions. Such procedures include in U.S. Patent 6,153,252. It may be advantageous to use the spray method or
- estradiol is described on the basis of the active ingredient 17 ⁇ -estradiol, it should be expressly mentioned that other estradiols can also be used, provided they show a similar effect.
- Fig. 1 is a schematic representation and shows a section of a cross section through a blood vessel.
- Fig. 2 is a perspective view and shows a stent, which with
- FIG. 3 is a schematic illustration and shows a cross section through the stent of FIG. 2.
- FIG. 4 is a schematic illustration and shows a top view of a device for coating the vascular support by means of a CVD method.
- FIG. 1 a section of a cross section through a blood vessel 10 is shown schematically in FIG. 1. It is the wall structure of an artery of the muscular type.
- the fat tissue in which the blood vessel runs is designated by 12.
- the outer layer (“tunica extema”) of the blood vessel 10 is designated by 14.
- An outer membrane 16 (“membrana elastica externa”) separates the outer layer 14 from a middle layer 18 ("tunica media”), which in turn is separated from an inner layer 22 ("tunica intima”) by an inner membrane 20 ("membrana elastica interna").
- the inner layer 22 consists of endothelium.
- the endothelium is a very thin layer, which consists only of a monolayer of cells.
- the middle layer 18 contains so-called smooth muscle cells.
- the middle layer 18 is exposed, so that the smooth muscle cells present there come into contact with the blood flowing in the blood vessel 10.
- the blood contains a number of substances which 'stimulate the growth of smooth muscle cells, which can lead to a narrowing of the blood vessel when this growth is not prevented. This growth is effectively prevented by inhibiting growth and by rapid formation of the endothelium.
- a stent 24 is shown.
- This stent 24 has a base body 26, which consists of a wire mesh made of medical stainless steel (316L). This is a vascular support, which is compressed in a so-called crimp device before the implantation.
- the surface of the base body 26 is coated with DLC. This is shown in FIG. 3 by an outer and an inner DLC layer 28 and 30, respectively.
- the surface of the DLC layer 28, 30 is coated with 17 ⁇ -estradiol.
- the 4 shows a device for coating vascular supports using a CVD method.
- the device contains a vacuum chamber 36.
- Vacuum chamber 36 are provided for stent gauges 38. (Four such vascular support receptacles 38 are shown in the schematic representation of FIG. 4, although the number can vary.)
- a receptacle 40 for holding the 17 ⁇ -estradiol.
- the receptacle 40 can be heated by a heating device shown as block 42.
- the stents Transducers 38 can be cooled by a cooling device shown as block 46.
- the stent gauges 38 are connected to a common cooling water circuit 48.
- the Schumchtung 42 for heating the receptacle 40 is connected to a timer 50 through which the heating time of the heater 42 is adjustable.
- a base body 26 of stent 24 is first made of medical grade stainless steel.
- the base body 26 is then coated with a DLC layer 28, 30. This is known per se and is not described in more detail here.
- the base body 26 coated with DLC is provided in one of the stent receptacles 38. Possibly further such base bodies 26 are provided in the further vascular support receptacles 38.
- 17 ⁇ -estradiol is filled in a form which is suitable for evaporation. For this the 17ß-estradiol can e.g. be dissolved in a suitable organic solvent.
- the vacuum chamber 36 is then closed and a vacuum is created in the vacuum chamber 36.
- Transducer 38 and thus the vessel supports located there are cooled to a defined temperature.
- the wall of the vacuum chamber 36 is heated to a defined temperature by means of the heating device 44.
- the receptacle 40 and thus the 17 ⁇ -estradiol solution located there is heated to a defined temperature or with a defined temperature profile by means of the heating device 42, the
- Timer 50 is set so that it turns off the heater 42 after a defined time.
- the temperatures defined by the heating devices 42 and 44 and by the cooling device 46 and the defined time of the time switching device 50 are determined beforehand in such a way that the stents located in the stent receptacles 38 are included 17ß-estradiol can be coated in a desired layer thickness. These parameters are preferably set such that the vascular supports are each coated with approximately 30-50 ⁇ g of 17 ⁇ -estradiol.
- a stent coated in this way e.g. is placed in a blood vessel, it is ensured that 17ß-estradiol is fed to the place where the stent is implanted. This then takes place simultaneously with the implantation of the stent.
- the amount of 17-estradiol added is selected so that the action time of the 17-estradiol corresponds essentially to the healing time of the vessel.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10107795.5 | 2001-02-13 | ||
DE10107795.5A DE10107795B4 (de) | 2001-02-13 | 2001-02-13 | Gefäßstütze mit einem Grundkörper, Verfahren zur Herstellung der Gefäßstütze, Vorrichtung zur Beschichtung der Gefäßstütze |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002064185A2 true WO2002064185A2 (de) | 2002-08-22 |
WO2002064185A3 WO2002064185A3 (de) | 2003-02-20 |
Family
ID=7674621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/001388 WO2002064185A2 (de) | 2001-02-13 | 2002-02-11 | VERFAHREN ZUR VERRINGERUNG VON FOLGEKOMPLIKATIONEN BEI DER IMPLANTATION VON GEFÄssSTÜTZEN |
Country Status (3)
Country | Link |
---|---|
US (2) | US6383215B1 (de) |
DE (1) | DE10107795B4 (de) |
WO (1) | WO2002064185A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020329A1 (en) * | 2001-08-30 | 2003-03-13 | Estrogen Vascular Technology, Lcc | Hormone-coated stent for preventing stenosis or atherosclerosis |
WO2004024206A1 (en) * | 2002-09-12 | 2004-03-25 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
EP2296722B1 (de) | 2008-05-31 | 2016-08-24 | Lothar Sellin | Medizinische einrichtung und verfahren zu ihrer herstellung |
CN107811726A (zh) * | 2016-09-13 | 2018-03-20 | 先健科技(深圳)有限公司 | 覆膜支架 |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7591846B2 (en) | 1996-11-04 | 2009-09-22 | Boston Scientific Scimed, Inc. | Methods for deploying stents in bifurcations |
US6599316B2 (en) | 1996-11-04 | 2003-07-29 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US6835203B1 (en) | 1996-11-04 | 2004-12-28 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US8211167B2 (en) | 1999-12-06 | 2012-07-03 | Boston Scientific Scimed, Inc. | Method of using a catheter with attached flexible side sheath |
US6692483B2 (en) | 1996-11-04 | 2004-02-17 | Advanced Stent Technologies, Inc. | Catheter with attached flexible side sheath |
US6325826B1 (en) * | 1998-01-14 | 2001-12-04 | Advanced Stent Technologies, Inc. | Extendible stent apparatus |
US20030129215A1 (en) * | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US7655030B2 (en) | 2003-07-18 | 2010-02-02 | Boston Scientific Scimed, Inc. | Catheter balloon systems and methods |
GB0100761D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
US8617231B2 (en) | 2001-05-18 | 2013-12-31 | Boston Scientific Scimed, Inc. | Dual guidewire exchange catheter system |
US6695920B1 (en) | 2001-06-27 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Mandrel for supporting a stent and a method of using the mandrel to coat a stent |
US20080145402A1 (en) * | 2001-09-10 | 2008-06-19 | Abbott Cardiovascular Systems Inc. | Medical Devices Containing Rapamycin Analogs |
US7326245B2 (en) * | 2002-01-31 | 2008-02-05 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
US7291165B2 (en) | 2002-01-31 | 2007-11-06 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
US7445629B2 (en) * | 2002-01-31 | 2008-11-04 | Boston Scientific Scimed, Inc. | Medical device for delivering biologically active material |
DE10228078B3 (de) * | 2002-06-18 | 2004-02-26 | Innovent E.V. Technologieentwicklung | Mittel zur Beschichtung von Implantaten sowie Verfahren zur Beschichtung von Implantaten |
AU2003291311A1 (en) * | 2002-11-07 | 2004-06-03 | Carbon Medical Technologies, Inc. | Biocompatible medical device coatings |
US7074276B1 (en) | 2002-12-12 | 2006-07-11 | Advanced Cardiovascular Systems, Inc. | Clamp mandrel fixture and a method of using the same to minimize coating defects |
US6957152B1 (en) | 2002-12-30 | 2005-10-18 | Advanced Cardiovascular Systems, Inc. | System and computer-based method for tracking an implantable medical device characteristic during a coating process |
US7494497B2 (en) * | 2003-01-02 | 2009-02-24 | Boston Scientific Scimed, Inc. | Medical devices |
US7001421B2 (en) * | 2003-02-28 | 2006-02-21 | Medtronic Vascular, Inc. | Stent with phenoxy primer coating |
AU2004237574A1 (en) * | 2003-03-13 | 2004-11-18 | Nitromed, Inc. | Nitrosated and nitrosylated compounds, compositions and methods of use |
JP2005046611A (ja) * | 2003-07-01 | 2005-02-24 | Medtronic Vascular Inc | 薬剤含有ポリマーが塗布されたステント用のエネルギーで活性化された接着剤層 |
WO2005018696A1 (en) * | 2003-08-19 | 2005-03-03 | Polybiomed Limited | Polymeric drug release system for medical devices |
US8298280B2 (en) | 2003-08-21 | 2012-10-30 | Boston Scientific Scimed, Inc. | Stent with protruding branch portion for bifurcated vessels |
US7344557B2 (en) | 2003-11-12 | 2008-03-18 | Advanced Stent Technologies, Inc. | Catheter balloon systems and methods |
US7435788B2 (en) | 2003-12-19 | 2008-10-14 | Advanced Cardiovascular Systems, Inc. | Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents |
US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
US9561309B2 (en) | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
WO2005122959A2 (en) | 2004-06-08 | 2005-12-29 | Advanced Stent Technologies, Inc. | Stent with protruding branch portion for bifurcated vessels |
US20050287184A1 (en) * | 2004-06-29 | 2005-12-29 | Hossainy Syed F A | Drug-delivery stent formulations for restenosis and vulnerable plaque |
CA2577108A1 (en) | 2004-08-31 | 2006-03-09 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
AT501408B1 (de) | 2004-12-07 | 2011-03-15 | Physikalisches Buero Steinmueller Gmbh | Biologische oberflächen |
JP2008543376A (ja) * | 2005-06-08 | 2008-12-04 | シー・アール・バード・インコーポレーテッド | 無機生体適合性カルシウム塩を有するグラフト及びステント |
ES2625807T3 (es) | 2005-06-17 | 2017-07-20 | C.R. Bard, Inc. | Injerto vascular con resistencia al retorcimiento tras la sujeción |
US7823533B2 (en) | 2005-06-30 | 2010-11-02 | Advanced Cardiovascular Systems, Inc. | Stent fixture and method for reducing coating defects |
US7735449B1 (en) | 2005-07-28 | 2010-06-15 | Advanced Cardiovascular Systems, Inc. | Stent fixture having rounded support structures and method for use thereof |
DE202006008702U1 (de) * | 2006-05-24 | 2007-09-27 | Biomed Est. | Beschichtung |
JP5118042B2 (ja) * | 2005-09-06 | 2013-01-16 | シー・アール・バード・インコーポレーテッド | 薬物結晶を含有する移植用インプラント |
WO2007056761A2 (en) | 2005-11-09 | 2007-05-18 | C.R. Bard Inc. | Grafts and stent grafts having a radiopaque marker |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US8821561B2 (en) | 2006-02-22 | 2014-09-02 | Boston Scientific Scimed, Inc. | Marker arrangement for bifurcation catheter |
US7985441B1 (en) | 2006-05-04 | 2011-07-26 | Yiwen Tang | Purification of polymers for coating applications |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
WO2008063780A2 (en) | 2006-10-12 | 2008-05-29 | C.R. Bard Inc. | Vascular grafts with multiple channels and methods for making |
US7713541B1 (en) * | 2006-11-21 | 2010-05-11 | Abbott Cardiovascular Systems Inc. | Zwitterionic terpolymers, method of making and use on medical devices |
US8486134B2 (en) | 2007-08-01 | 2013-07-16 | Boston Scientific Scimed, Inc. | Bifurcation treatment system and methods |
JP5504173B2 (ja) | 2007-12-31 | 2014-05-28 | ボストン サイエンティフィック サイムド,インコーポレイテッド | 血管分岐部の処置のためのカテーテルアセンブリ |
US8377108B2 (en) | 2008-06-02 | 2013-02-19 | Boston Scientific Scimed, Inc. | Staggered two balloon bifurcation catheter assembly and methods |
EP2299945B1 (de) | 2008-06-05 | 2016-03-23 | Boston Scientific Scimed, Inc. | Ballonbehandlung von gabelförmigen lumen |
WO2009149410A1 (en) | 2008-06-05 | 2009-12-10 | Boston Scientific Scimed, Inc. | Deflatable bifurcated device |
CN102215780B (zh) | 2008-09-25 | 2015-10-14 | 高级分支系统股份有限公司 | 部分压接支架 |
US11298252B2 (en) | 2008-09-25 | 2022-04-12 | Advanced Bifurcation Systems Inc. | Stent alignment during treatment of a bifurcation |
US8769796B2 (en) | 2008-09-25 | 2014-07-08 | Advanced Bifurcation Systems, Inc. | Selective stent crimping |
CA2787002A1 (en) * | 2010-01-25 | 2011-07-28 | Concept Medical Research Private Limited | A method and an insertable medical device for delivering one or more pro-healing agents to a target site within a blood vessel post-deployment of a stent |
WO2011119883A1 (en) | 2010-03-24 | 2011-09-29 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
CN103037816B (zh) | 2010-03-24 | 2018-12-28 | 高级分支系统股份有限公司 | 用于处理分叉部的系统和方法 |
DE202011111004U1 (de) | 2010-03-24 | 2018-04-17 | Advanced Bifurcation Systems, Inc. | Systeme für das ostiale Stenting einer Bifurkation |
AU2011232358B2 (en) | 2010-03-24 | 2015-10-08 | Advanced Bifurcation Systems Inc. | Methods and systems for ostial stenting of a bifurcation |
WO2012109382A2 (en) | 2011-02-08 | 2012-08-16 | Advanced Bifurcation Systems, Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
EP2672932B1 (de) | 2011-02-08 | 2018-09-19 | Advanced Bifurcation Systems, Inc. | System zur behandlung einer gabelung mit einem vollständig gecrimpten stent |
CN109419570A (zh) * | 2017-08-30 | 2019-03-05 | 先健科技(深圳)有限公司 | 覆膜支架及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002100A1 (en) * | 1996-07-16 | 1998-01-22 | Anson Medical Limited | Surgical implants and delivery systems therefor |
WO1998056312A1 (en) * | 1997-06-13 | 1998-12-17 | Scimed Life Systems, Inc. | Stents having multiple layers of biodegradable polymeric composition |
US5866561A (en) * | 1997-08-21 | 1999-02-02 | Scimed Life Systems, Inc. | Local delivery of estrogen for angiogenesis |
DE19744135C1 (de) * | 1997-09-29 | 1999-03-25 | Schering Ag | Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe |
WO1999056663A2 (en) * | 1998-05-05 | 1999-11-11 | Scimed Life Systems, Inc. | Stent with smooth ends |
WO1999062572A1 (en) * | 1998-06-03 | 1999-12-09 | N.V. Bekaert S.A. | Stents with a diamond like coating |
WO2001021157A2 (en) * | 1999-09-21 | 2001-03-29 | Institut De Cardiologie De Montreal | Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197013B1 (en) * | 1996-11-06 | 2001-03-06 | Setagon, Inc. | Method and apparatus for drug and gene delivery |
EP1119379A1 (de) * | 1998-09-02 | 2001-08-01 | Boston Scientific Limited | Arzneimittelabgabevorrichtung für stents |
WO2001047451A1 (en) * | 1999-12-29 | 2001-07-05 | Gishel New | Apparatus and method for delivering compounds to a living organism |
US6471979B2 (en) * | 1999-12-29 | 2002-10-29 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
GB0100760D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
-
2001
- 2001-02-13 DE DE10107795.5A patent/DE10107795B4/de not_active Expired - Fee Related
- 2001-04-20 US US09/839,249 patent/US6383215B1/en not_active Expired - Fee Related
-
2002
- 2002-02-11 WO PCT/EP2002/001388 patent/WO2002064185A2/de not_active Application Discontinuation
- 2002-02-27 US US10/087,065 patent/US20020111670A1/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002100A1 (en) * | 1996-07-16 | 1998-01-22 | Anson Medical Limited | Surgical implants and delivery systems therefor |
WO1998056312A1 (en) * | 1997-06-13 | 1998-12-17 | Scimed Life Systems, Inc. | Stents having multiple layers of biodegradable polymeric composition |
US5866561A (en) * | 1997-08-21 | 1999-02-02 | Scimed Life Systems, Inc. | Local delivery of estrogen for angiogenesis |
DE19744135C1 (de) * | 1997-09-29 | 1999-03-25 | Schering Ag | Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe |
WO1999056663A2 (en) * | 1998-05-05 | 1999-11-11 | Scimed Life Systems, Inc. | Stent with smooth ends |
WO1999062572A1 (en) * | 1998-06-03 | 1999-12-09 | N.V. Bekaert S.A. | Stents with a diamond like coating |
WO2001021157A2 (en) * | 1999-09-21 | 2001-03-29 | Institut De Cardiologie De Montreal | Local delivery of 17-beta estradiol for preventing vascular intima hyperplasia and for improving vascular endothelium function after vascular injury |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003020329A1 (en) * | 2001-08-30 | 2003-03-13 | Estrogen Vascular Technology, Lcc | Hormone-coated stent for preventing stenosis or atherosclerosis |
WO2004024206A1 (en) * | 2002-09-12 | 2004-03-25 | Estrogen Vascular Technology, Llc | Apparatus and method for delivering compounds to a living organism |
EP2296722B1 (de) | 2008-05-31 | 2016-08-24 | Lothar Sellin | Medizinische einrichtung und verfahren zu ihrer herstellung |
CN107811726A (zh) * | 2016-09-13 | 2018-03-20 | 先健科技(深圳)有限公司 | 覆膜支架 |
WO2018049868A1 (zh) * | 2016-09-13 | 2018-03-22 | 先健科技(深圳)有限公司 | 覆膜支架 |
Also Published As
Publication number | Publication date |
---|---|
US6383215B1 (en) | 2002-05-07 |
WO2002064185A3 (de) | 2003-02-20 |
US20020111670A1 (en) | 2002-08-15 |
DE10107795B4 (de) | 2014-05-15 |
DE10107795A1 (de) | 2002-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10107795B4 (de) | Gefäßstütze mit einem Grundkörper, Verfahren zur Herstellung der Gefäßstütze, Vorrichtung zur Beschichtung der Gefäßstütze | |
DE69727777T2 (de) | Verfahren und Vorrichtung zum Anbringen medizinische Wirkstoffe freisetzender Beschichtungen | |
DE60217505T2 (de) | Vorrichtungen zur Abgabe von therapeutischen Mitteln mit variablem Freisetzungsprofil | |
DE60032912T2 (de) | Poröse prothese und verfahren zur abscheidung von substanzen in den poren | |
DE60032102T2 (de) | Beschichtung für einen stent | |
DE69730475T2 (de) | Beschichteter Stent und Verfahren zur Wirkstoffabgabe | |
DE69533892T2 (de) | Stent mit arzneistoffabgabe | |
DE69820616T2 (de) | Lumenendoprothese | |
DE69637302T2 (de) | Verfahren zur Beschichtung von Arzneimittel enthaltenden Stents | |
DE69736343T2 (de) | Vaskuläre und endoluminale Stents | |
EP2296587B1 (de) | Metallischer stent zur behandlung von läsionen in blutgefässen mit einer verpackung | |
EP1984033B1 (de) | Verfahren zur umhüllung eines stents | |
DE602004010344T2 (de) | Katheter ohne Ballon zum Einsetzen eines Stents | |
DE102004029611A1 (de) | Implantat zur Freisetzung eines Wirkstoffs in ein von einem Körpermedium durchströmtes Gefäß | |
DE10237571A1 (de) | Endovaskuläres Implantat mit aktiver Beschichtung | |
EP0578998A1 (de) | In der Körper eines Patienten perkutan implantierbare Endoprothese | |
DE29624503U1 (de) | Arzneimittel-freisetzender beschichteter Stent | |
EP1827301A1 (de) | Stützprothese | |
DE602004011897T2 (de) | Stent-Transplantat mit Elutionsöffnungen | |
EP1711213B1 (de) | Implantat zur freisetzung eines wirkstoffs in ein von einem körpermedium durchströmtes gefäss | |
DE10031199A1 (de) | Implantierbare Vorrichtung mit einem Bestandteil aus Poly-Aminosäure | |
EP2491965A2 (de) | Implantat und Verfahren zur Herstellung desselben | |
EP1475053B1 (de) | Verfahren zur Herstellung eines medizinischen Implantates | |
WO2020254454A1 (de) | Stent mit sofort ablösbarer beschichtung | |
DE102007029672A1 (de) | Implantat und Verfahren zu dessen Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |